CurveBeam AI
(ASX:CVB) Share Price and News
About CurveBeam AI
CurveBeam AI (ASX:CVB) is the leading medical technology company in the development and commercialization of sophisticated medical computed tomography scanners. Founded to change the face of diagnostic imaging, CurveBeam AI has positioned itself at the forefront of medical innovation.
HiRise is the flagship product, a third-generation CT scanner that had been FDA cleared since 2020. HiRise represents the leading edge of imaging technology, designed for high-resolution scans with a precision yet to be paralleled.
Not limiting itself to the development of hardware, CurveBeam AI develops intelligent AI algorithms and embeds them into its scanners. These algorithms not only improve the efficiency of the HiRise but also will be released as separate products in the very near future. CurveBeam AI converges premier imaging with strong AI-driven insights, thereby freeing up a gamut of innovations in medical diagnostics and improving patient outcomes across the healthcare sector.
History of CurveBeam AI
CurveBeam AI as a company was only founded in 2022 and listed on the ASX in 2023 as part of an M&A deal of StraxCorp and CurveBeam - the former bringing the BMD (Bone Mineral Density) algorithms and the latter bringing the physical scanners.
The former company was founded in 2009 when its founder Arun Singh (who is still part of the company today), broke his foot and found scanners could only guess the extent of his injuries as they could only work with the patient lying down and this is unideal for foot injuries and while X-rays could be done upright, they were only 2D. The first FDA clearance was in 2012 and the latest generation was approved in 2020. Also in 2020, then president elect Joe Biden underwent a scan using CVB following his suffering of a hairline foot fracture.
The company's IPO came in 2023 during which it raised $25m. In the years immediately following the listing through 2024 and into 2025, CurveBeam AI reported revenue growth and strategic progress. The company also expanded commercial agreements such as a distribution and referral deal in Australia and New Zealand with medical device major Stryker.
Despite progress, the company remained loss-making, though operating losses and cash burn were reduced compared to earlier periods. But in late 2025 and early 2026, more progress was made. the company signed a 10-year exclusive partnership with a Chinese consortium led by Shandong Weigao’s orthopaedic division to commercialise its WBCT and AI products across China and neighbouring territories, including potential equity investment totaling up to A$10 million and royalty arrangements.
Future Outlook of CurveBeam AI (ASX:CVB)
Looking ahead, CurveBeam’s future outlook hinges on many factors. The most obvious of which is product adoption and growth - continued traction for HiRise and related SaaS AI modules in major markets (U.S., Europe, China) will be central. Success in China, if regulatory and commercial milestones are achieved, could drive significant revenue expansion.
Agreements with established distributors and clinical partners will also improve commercial reach, but execution will be key.
Is CurveBeam AI (ASX:CVB) a Good Stock to Buy?
CurveBeam AI may appeal to investors comfortable with speculative, early-stage medical technology stocks with long-term potential, but it also carries significant execution and growth risk. Prospective investors should assess personal risk tolerance, stay updated on regulatory and market developments, and consider seeking advice from a qualified financial adviser before making investment decisions.
CurveBeam AI is widely regarded in the ASX small-cap segment as a high-risk, high-upside speculative investment rather than a stable, low-risk stock.
It operates in a competitive med-tech space where long sales cycles, regulatory requirements and the need for capital growth investment introduce execution risk. Share price performance has reflected volatility since IPO, and while strategic partnerships provide validation, the business is not yet consistently profitable and remains dependent on future adoption and funding.
Our Stock Analysis
CurveBeam AI (ASX:CVB) Jumps 20% as China Greenlights A$4M Equity Injection
CurveBeam AI Gets the Green Light CurveBeam AI (ASX:CVB) shares surged 20% today after the company received formal China ODI…
CurveBeam AI Rockets 28% After China Deal Opens Door to 38,000 Hospitals
Could CurveBeam Be The Next 4DMedical CurveBeam AI’s share price jumped 28% today after the company released its quarterly update…
CurveBeam AI Jumps 37%: Opportunity or Overreaction?
CurveBeam AI Surges 37% as Investor Optimism Builds CurveBeam AI (ASX: CVB) caught the market’s attention this week after its…
Curvebeam AI (ASX:CVB): Could this company be the next Pro Medicus?
Not many ASX medtech companies can boast of a then US President elect as a patient, but Curvebeam AI (ASX:CVB)…
Frequently Asked Questions
HiRise is a point of care CT scanner that uses Cone Beam Technology and is functional - Weight Bearing. These features allow medical professionals (such as orthopaedic specialists) to do their job better by generating better images more likely to capture medical ailments and do so faster than competing technologies.